WILSON SONSINI

Weigang Lu

LAW CLERK

Patents and Innovations

Boston

wlu@wsgr.com
617-598-7868

FOCUS AREAS

Intellectual Property

Life Sciences

Patents and Innovations

EXPERIENCE

Dr. Weigang Lu is a law clerk in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His technical expertise spans across a variety of fields, including biotechnology, pharmaceutics, and chemistry.

Prior to joining Wilson Sonsini, Weigang was a patent agent in another law firm, where he gained extensive experience in patent prosecution and IP due diligence in areas including antibodies, diagnostics, RNA therapeutics, gene/cell therapies, small molecule drugs, polymers, and batteries. Before his legal career, Weigang was a postdoctoral fellow in the Department of Immunology at Harvard Medical School, where he investigated use of gut microbiome-related molecules to improve immuno-oncology. During his doctoral training at the Complex Carbohydrate Research Center at the University of Georgia, Weigang studied human glycan synthesis and glycobiology.

Weigang is admitted to the U.S. Patent and Trademark Office. He is not yet admitted to any jurisdiction and therefore not yet authorized to practice law.

CREDENTIALS

Education

- J.D., Northeastern University School of Law, 2025
- Ph.D., Organic Chemistry, University of Georgia, 2018
- M.S., Pharmaceutical Sciences, Peking University, 2013
- B.S., Pharmaceutical Science, Peking University, 2011

Admissions

- U.S. Patent and Trademark Office
- Not yet admitted to practice in any jurisdiction

INSIGHTS

Select Publications

- Co-author, “The 3-O-sulfation of heparan sulfate modulates protein binding and lyase degradation,” 118 *Proc. Natl. Acad. Sci. USA* 1-12, 2021
- Co-author, “Fully Synthetic Heparan Sulfate-Based Neural Tissue Construct That Maintains the Undifferentiated State of Neural Stem Cells,” 14 *ACS Chemical Biology* 1921-1929, 2019
- Co-author, “Controlled Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides,” 57 *Angew. Chem. Intl. Ed.* 5340-5344, 2018
- Co-author, “Negative Electron Transfer of Dissociation Sequencing of 3-O-Sulfation Containing Heparan Sulfate Oligosaccharides,” 29 *J. Am. Soc. Mass. Spectrom.* 1262-1272, 2018
- Co-author, “Heparan Sulfate Microarray Reveals Heparan Sulfate-Protein Binding Exhibits Different Ligand Requirements,” 139 *J. Am. Chem. Soc.* 9534-9543, 2017

- Co-author, “Integrated Approach to Identify Heparan Sulfate Ligand Requirements of Robo1,” 138 *J. Am. Chem. Soc.* 13059-13067, 2016
- Co-author, “General Aspects in O-Glycosidic Bond Formation,” Chapter 3, *Glycochemical Synthesis: Strategies and Applications* 69-95, 2016

TECHNICAL FLUENCY

Biological Sciences and Biotechnology

- Antibody
- Bioconjugation
- Biologics
- Cancer therapeutics
- CAR-T cells
- Cell therapy
- Glycobiology
- Immuno-oncology
- Immunology
- T cell biology

Therapeutics and Drug Discovery

- Antimicrobial agents
- Biosimilars
- CRISPR
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Neuropharmacology
- Peptide therapeutics
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- RNA interference (RNAi)
- Small molecule synthesis
- Small molecules
- Vaccines

Chemistry and Material Science

- Catalysis
- Chemical synthesis
- Chemistry
- Chemoenzymatic synthesis
- Materials chemistry
- Organic chemistry
- Peptidomimetics
- Polymers
- Protein engineering

Miscellaneous

- Formulations